CAS No.55837-30-4,Lysine clonixinate Suppliers

Detail of "55837-30-4"

CAS Number:

55837-30-4

Name:

Lysine clonixinate

Molecular Structure:

Formula:

C₁₃H₁₁ClN₂O₂^.C₆H₁₄N₂O₂

Molecular Weight:

408.88

Synonyms:

L 104;Clonixin lysine salt;3-Pyridinecarboxylic acid, 2-((3-chloro-2-methylphenyl)amino)-, compd. with L-lysine (1:1);2-[(3-chloro-2-methyl-phenyl)amino]pyridine-3-carboxylic acid; (2S)-2,6-diaminohexanoic acid;2-(2-Methyl-3-chloroanilino)lysine nicotinate;L-Lysine, mono(2-((3-chloro-2-methylphenyl)amino)-3-pyridinecarboxylate);L-Lysine,compounds,mono[2-[(3-chloro-2- methylphenyl)amino]-3-pyridinecarboxylate];L-104;Clonixin lysinate;

Melting Point:

208-214 °C (dec.)

Boiling Point:

410.2 °C at 760mmHg

Flash Point:

201.9 °C

Appearance:

White to off-white solid

Reference

Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon: Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. Russmann, Stefan; Dilger, Karin; Trenk, Dietmar; Nagyivanyi, Patricia; Jahnchen, Eberhard (Department of Clinical Pharmacology, Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany). Arzneimittel-Forschung, 51(11), 891-895 (English) 2001 Editio Cantor Verlag. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The effect of the non-steroidal anti-inflammatory drug lysine clonixinate ([2-(3-chloro-o-toluidino)nicotinic acid]-L-lysinate, CAS 55837-30-4) on the pharmacokinetics and anticoagulant activity of phenprocoumon (4-hydroxy-3-(1-phenylpropyl)-coumarin, CAS 435-97-2) was investigated in an open, randomized, two-fold, cross-over study in 12 healthy male volunteers. These subjects received a single dose of 18 mg phenprocoumon without or with concomitant treatment with lysine clonixinate (125 mg five times a day for 3 days before and 13 days after ingestion of a single dose of phenprocoumon). Pharmacokinetic parameters of phenprocoumon following oral administration were: CL/f: 0.779±0.157 mL/min, half-life of elimination: 147.2±19.9 h; free fraction in serum: 0.51±0.20%. These parameters were not significantly altered by concomitant treatment with lysine clonixinate. Prothrombin time increased from 13.3±1.3 s (at time 0) to 17.7±2.7 s following phenprocoumon and from 13.3±1.2 s to 18.0±2.2 s following combined administration. Prothrombin time returned to the pretreatment values 240 h after administration of phenprocoumon. The integrated effect (AUEC0-288 h) was identical following both treatments (4,303±461 and 4,303±312 s ′ h for phenprocoumon alone and phenprocoumon with lysine clonixinate, resp.). Thus, lysine clonixinate administered in therapeutic doses does not affect the pharmacokinetics and anticoagulant activity of phenprocoumon.

Detail of "55837-30-4"

Lysine clonixinate

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

Exhibitions

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

CAS No.55837-30-4 Lysine clonixinate

Reference